

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications  
under 37 CFR 1.53(b))

Attorney Docket No. **C1037/7017HCL/MAT**

First Named Inventor or Application Identifier

**BRATZLER, Robert L.**

Express Mail Label No. **EL711263038US**

Date of Deposit **March 5, 2001**

JG929 U.S.P.T.O.  
10/05/03

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents

<p>1. <input type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</p> <p>2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. <input type="checkbox"/> Statement filed in prior application, status still proper and desired.</p> <p>3. X Specification -Total pages - 73 66 - pages description 1 - pages abstract 6 - pages claims      36- Total claims</p> <p>4. <input type="checkbox"/> Drawing(s) (35 USC 113) - Total sheets <input type="checkbox"/> Informal    <input type="checkbox"/> Formal      - Total drawings</p> <p>5. <input type="checkbox"/> Oath or Declaration - Total pages a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) (Note Box 6 below) <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>6. <input type="checkbox"/> Incorporation by Reference (usable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. See 18.</p> <p>7. <input type="checkbox"/> Application Data Sheet, See 37 CFR 1.76</p>	<p>ADDRESS TO: Box Patent Application Commissioner for Patents Washington, DC 20231</p> <p>8. <input type="checkbox"/> CD-ROM or CD-R, in duplicate, large table or Computer Program (Appendix)</p> <p>9. X Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. X Computer Readable Form (CRF) b. X Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. X paper (identical to computer copy) c. X Statement verifying identity of above copies</p>
---	--

**ACCOMPANYING APPLICATION PARTS**

- 10.  Assignment Papers/cover sheet & documents(s)
- 11.  37 CFR 3.73(b) Statement  
(when there is an assignee)  
 Power of Attorney
- 12.  English Translation of Document (if applicable)
- 13.  Information Disclosure Statement/PTO-1449  
 Copies of IDS Citations
- 14.  Preliminary Amendment
- 15. X Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
- 16.  Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
- 17. X This application claims priority under Title 35 §119(e), of United States Provisional Application No. 60/187,214, filed March 3, 2000, and entitled IMMUNOSTIMULATORY NUCLEIC ACIDS AND CANCER MEDICAMENT COMBINATION THERAPY FOR THE TREATMENT OF CANCER, the entire contents of which are incorporated herein by reference.

18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:


Continuation    Divisional    Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_, filed on \_\_\_\_\_, entitled \_\_\_\_\_ and now \_\_\_\_\_.

Prior application information: Examiner \_\_\_\_\_ Group Art Unit: \_\_\_\_\_

For CONTINUATION OR DIVISIONAL APPS only The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

Correspondence address below

CUSTOMER NUMBER	 <b>23628</b> PATENT TRADEMARK OFFICE
20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
NAME	Helen C. Lockhart, Reg. No. 39248
SIGNATURE	
DATE	March 5, 2001

**Express Mail No: EL711263038US**  
**Date of Deposit: March 5, 2001**  
**Attorney Docket No: C1037/7017**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: BRATZLER, Robert L. et al.  
Filed: Herewith  
For: IMMUNOSTIMULATORY NUCLEIC ACIDS AND  
CANCER MEDICAMENT COMBINATION THERAPY FOR  
THE TREATMENT OF CANCER

Box: Patent Application  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**STATEMENT PURSUANT TO 37 CFR 1.821(f)**

Sir:

This statement is made pursuant to 37 CFR 1.821(f). Applicant encloses herewith a copy of the Sequence Listing and a computer readable diskette. Applicant's attorney states that the content of the paper copy of the Sequence Listing and the computer readable diskette contain the identical information.

Respectfully submitted,



Helen C. Lockhart  
Reg. No. 39,248  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211  
(617)720-3500

Docket No.C1037/7017  
March 5, 2001  
**X03/03/01**